Evangelos J Giamarellos-Bourboulis
Overview
Explore the profile of Evangelos J Giamarellos-Bourboulis including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
434
Citations
12744
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
2.
Arapis A, Panagiotopoulos D, Giamarellos-Bourboulis E
Burns Trauma
. 2025 Feb;
13:tkaf001.
PMID: 40007937
Precision immunotherapy signifies the administration of the required type of immune intervention tailored to the state of immune activation at the appropriate time window. The classification of patients into the...
3.
Spanou V, Andriopoulou T, Giamarellos-Bourboulis E, Netea M
EMBO Mol Med
. 2025 Jan;
PMID: 39843630
Recent studies argue for a novel concept of the role of chromatin as a carrier of epigenetic memory through cellular and organismal generations, defining and coordinating gene activity states and...
4.
Scheer C, Giamarellos-Bourboulis E, Ferrer R, Idelevich E, Annane D, Artigas A, et al.
Am J Respir Crit Care Med
. 2025 Jan;
PMID: 39787606
Rationale: Early detection, standardized therapy, adequate infrastructure and strategies for quality improvement should constitute essential components of every hospital's sepsis plan. Objectives: To investigate the extent to which recommendations from...
5.
Netea M, van de Veerdonk F, Giamarellos-Bourboulis E
JAMA
. 2025 Jan;
333(8):661-662.
PMID: 39761040
No abstract available.
6.
Antonakos N, Giamarellos-Bourboulis E, Niederman M
Curr Opin Infect Dis
. 2024 Dec;
38(2):190-197.
PMID: 39693116
Purpose Of Review: Define the utility of adjunctive macrolide therapy in patients with more severe forms of community-acquired pneumonia (CAP). Recent Findings: Guidelines recommend adjunctive macrolide therapy as an option...
7.
Bloos F, Bogatsch H, Netea M, Giamarellos-Bourboulis E, Bauer M
Intensive Care Med
. 2024 Dec;
51(1):179-181.
PMID: 39665860
No abstract available.
8.
Akinosoglou K, Leventogiannis K, Tasouli E, Kakavoulis N, Niotis G, Doulou S, et al.
Int J Antimicrob Agents
. 2024 Dec;
65(2):107406.
PMID: 39647798
Background: In the ACCESS trial, the addition of clarithromycin to standard-of-care antibiotics (SoC) enhanced early clinical response and attenuated the inflammatory burden in adults with community-acquired pneumonia (CAP) requiring hospitalisation....
9.
Kyriazopoulou E, Akinosoglou K, Florou E, Kouriannidi E, Bogosian A, Tsachouridou O, et al.
Int J Antimicrob Agents
. 2024 Dec;
65(1):107405.
PMID: 39647797
Background: Anakinra was approved by the European Medicines Agency and received Emergency Use Authorization by the United States Food and Drug Administration for patients with COVID-19 pneumonia at risk for...
10.
Kimball A, Bechara F, Badat A, Giamarellos-Bourboulis E, Gottlieb A, Jemec G, et al.
Br J Dermatol
. 2024 Nov;
PMID: 39611771
Background: SUNSHINE and SUNRISE demonstrated sustained clinical efficacy of secukinumab in patients with moderate-to-severe hidradenitis suppurativa (HS) through 52 weeks. Patients completing the core trials could enter a 4-year extension...